SET/TAF-I anticorps

N° du produit ABIN4620361

Détail du produit anti-SET/TAF-I anticorps

Antigène: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SET/TAF-I est non-conjugé

Application: Western Blotting (WB)

Specificité: This antibody detects I2PP2A / SET, widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor.

Purification: Affinity chromatography

Immunogène: Synthetic peptide derived from the human SET protein

Isotype: IgG

Information d'application

Indications d'application: Western blot (1: 400 dilution).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate buffered saline with 0.08 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Stockage commentaire: Store the product (in aliquots) at -20 °C to -70 °C. Can be shipped at 2 - 8 °C.

Références pour anticorps anti-SET/TAF-I (ABIN4620361)

Shih, Shih, Lee, Huang, Wang, Chen, Tsai: "Particle size distributions and health-related exposures of polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) of sinter plant workers." dans: Chemosphere, (2009) (PubMed).

Détails sur SET/TAF-I

Antigène: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Autre désignation: SET / I2PP2A (SET Produits)

Synonymes: anticorps 2PP2A, anticorps I2PP2A, anticorps IGAAD, anticorps IPP2A2, anticorps PHAPII, anticorps TAF-I, anticorps TAF-IBETA, anticorps 2610030F17Rik, anticorps 5730420M11Rik, anticorps AA407739, anticorps I-2PP2A, anticorps StF-IT-1, anticorps 2pp2a, anticorps i2pp2a, anticorps igaad, anticorps ipp2a2, anticorps phapii, anticorps set, anticorps set-a, anticorps set-b, anticorps taf-ibeta, anticorps wu:fb30g11, anticorps wu:fd16c08, anticorps SET nuclear proto-oncogene, anticorps SET nuclear oncogene, anticorps SET translocation, anticorps SET nuclear proto-oncogene L homeolog, anticorps SET nuclear proto-oncogene b, anticorps SET, anticorps Set, anticorps LOC403555, anticorps set.L, anticorps setb

Sujet: Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.Synonyms: I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I

ID gène: 6418

NCBI Accession: NP_001116293

UniProt: H0UI37

Pathways: Apoptose